| scholarly article | Q13442814 |
| P2093 | author name string | Damiano Baldassarre | |
| Joseph P Kitzmiller | |||
| Philip F Binkley | |||
| Adam M Suhy | |||
| Katherine Hartmann | |||
| Saurabh R Pandey | |||
| P2860 | cites work | Newly identified loci that influence lipid concentrations and risk of coronary artery disease | Q28264535 |
| High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1) | Q28269517 | ||
| Cholesteryl Ester Transfer Protein (CETP) polymorphisms affect mRNA splicing, HDL levels, and sex-dependent cardiovascular risk | Q28731522 | ||
| SLCO1B1 variants and statin-induced myopathy--a genomewide study | Q29619028 | ||
| Growing epidemic of coronary heart disease in low- and middle-income countries | Q33828135 | ||
| The use of phenome-wide association studies (PheWAS) for exploration of novel genotype-phenotype relationships and pleiotropy discovery | Q35049307 | ||
| Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs | Q35642257 | ||
| Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy | Q35909737 | ||
| Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with type 2 diabetes: a go-DARTS study | Q35964012 | ||
| Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response, and cardiovascular disease incidence in PROSPER. | Q36045787 | ||
| Antibody levels correlate with creatine kinase levels and strength in anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy. | Q36434543 | ||
| Effect of cytochrome P450 3A5 genotype on atorvastatin pharmacokinetics and its interaction with clarithromycin. | Q37017426 | ||
| Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention | Q37449898 | ||
| Lack of effect of genetic polymorphisms of SLCO1B1 on the lipid-lowering response to pitavastatin in Chinese patients | Q37728163 | ||
| Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin. | Q42757090 | ||
| Pharmacogenetic interactions between ABCB1 and SLCO1B1 tagging SNPs and the effectiveness of statins in the prevention of myocardial infarction | Q42936467 | ||
| Comprehensive whole-genome and candidate gene analysis for response to statin therapy in the Treating to New Targets (TNT) cohort | Q43209469 | ||
| Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in the Rotterdam Study | Q44077542 | ||
| Pharmacogenetic study of statin therapy and cholesterol reduction | Q44938097 | ||
| Lipid-lowering response to statins is affected by CYP3A5 polymorphism | Q45000633 | ||
| Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: individual patient meta-analysis of 13,677 subjects. | Q45227730 | ||
| ABCB1 haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin. | Q46111557 | ||
| CETP genotype predicts increased mortality in statin-treated men with proven cardiovascular disease: an adverse pharmacogenetic interaction | Q46289075 | ||
| A paucimorphic variant in the HMG-CoA reductase gene is associated with lipid-lowering response to statin treatment in diabetes: a GoDARTS study. | Q46348510 | ||
| CYP3A53A allele is associated with reduced lowering-lipid response to atorvastatin in individuals with hypercholesterolemia | Q46410827 | ||
| Variation in the 3-hydroxyl-3-methylglutaryl coenzyme a reductase gene is associated with racial differences in low-density lipoprotein cholesterol response to simvastatin treatment | Q46520652 | ||
| An association study of 43 SNPs in 16 candidate genes with atorvastatin response | Q46653214 | ||
| The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment | Q46830670 | ||
| Effect of polymorphic CYP3A5 genotype on the single-dose simvastatin pharmacokinetics in healthy subjects. | Q53581879 | ||
| Regulation of plasma HDL cholesterol and subfraction distribution by genetic and environmental factors. Associations between the TaqI B RFLP in the CETP gene and smoking and obesity. | Q54103484 | ||
| Genetic analysis of fluvastatin response and dyslipidemia in renal transplant recipients | Q57750555 | ||
| The Role of a Common Variant of the Cholesteryl Ester Transfer Protein Gene in the Progression of Coronary Atherosclerosis | Q60233014 | ||
| Contribution of cytochrome P450 3A4 and 3A5 to the metabolism of atorvastatin | Q94705921 | ||
| Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability | Q95805177 | ||
| P433 | issue | 86 | |
| P921 | main subject | biomarker | Q864574 |
| pharmacogenomics | Q1152227 | ||
| P304 | page(s) | 45-51 | |
| P577 | publication date | 2013-08-01 | |
| P1433 | published in | Discovery Medicine | Q5281940 |
| P1476 | title | Statin pharmacogenomics: pursuing biomarkers for predicting clinical outcomes | |
| P478 | volume | 16 |
| Q35799847 | ABCB1 C3435T polymorphism and the lipid-lowering response in hypercholesterolemic patients on statins: a meta-analysis |
| Q30490270 | Economic Evaluation of a Pharmacogenomics Test for Statin-Induced Myopathy in Cardiovascular High-Risk Patients Initiating a Statin. |
| Q39514336 | Frequency distribution of polymorphisms of CYP2C19, CYP2C9, VKORC1 and SLCO1B1 genes in the Yakut population |
| Q57285996 | KIF6 gene as a pharmacogenetic marker for lipid-lowering effect in statin treatment |
| Q26771550 | Lipids, blood pressure and kidney update 2015 |
| Q63443841 | Sub-optimal cholesterol response to initiation of statins and future risk of cardiovascular disease |
Search more.